By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Next-generation sequencing technology firm GnuBio has completed its Series A equity financing round raising $8 million, which the company will use to accelerate the beta program for its platform.

The round had 12 participants, though company CEO John Boyce declined to identify them. GnuBio raised the first $3 million of the round in November and raised the remaining $5 million upon hitting certain milestones, he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.